Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravitreal Cerliponase Alfa for Retinal Disease in CLN2
NCT05152914Phase 2Active, not recruiting
- Start
- Nov 2021
- Primary completion
- Mar 2026
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of cerliponase alfa in neuronal ceroid lipofuscinosis type 2 (CLN2). Primary endpoint: Development of unacceptable toxicity at 2 years. Started Nov 2021; status: active, not recruiting.
02
Drugs
cerliponase alfa
03
Conditions
neuronal ceroid lipofuscinosis type 2 (CLN2)
Beyond the preview
Go deeper on NCT05152914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05152914.